Loading
Relmada Therapeutics, Inc. Stock: price and insider trades · United States
2 insiders bought €1.4M of shares over the last 90 days, the latest by TRAVERSA SERGIO, filed 11 Sept 2026.
Relmada Therapeutics, Inc.: what insiders have been doing
Relmada Therapeutics, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Between 22 October 2025 and 22 October 2026, 4 insiders published 10 filings.
Only purchases show up on the open market, 10 purchases in all worth €3.5M, filed by 4 insiders. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Shenouda Maged filed the largest purchase, €958k, on 6 November 2025. On the buying side, the filings list 2 senior executives, 1 finance chief and 1 chief executive among the declarants.
With 10 filings in twelve months, the company is quieter than the median of 24 filings across the 3,171 companies we follow on the same exchange. Our records for Relmada Therapeutics, Inc. go back to 2016, with 52 purchases and 81 sales on the open market in total.
In all, 10 purchases were made within 30 days of a purchase by another insider of the company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The most recent open-market purchase was published on 11 September 2026, 42 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. US insiders must file a Form 4 within two business days of a trade.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
181
Thresholds
n/a
Buy Volume
€6M
52 ops. · all time
Sell Volume
€5M
81 ops. · all time
Who traded when
BuySaleSergio Traversa10 buys
Maged Shenouda7 buys
Chuck Ence2 buys
Paul Edward Kelly2 buys
Since the insiders bought
- -30.2%Entry US$4.44 · Close 16 Oct 2026 US$3.10
- -30.2%Entry US$4.44 · Close 16 Oct 2026 US$3.10
- +35.8%Entry US$2.65 · Close at T+90 US$3.60
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 24,917 of 26,248 companies
15.7
score / 100
Value13
Quality18
FCF yld-13%
Earn yld-16%
EV/EBITDA·
ROE-56%
Gross mgn21%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.36
Analyst consensus
4 analysts1.25/5
US$9.00Target US$10.75(+220%)US$12.00
Income statement
RevenueUS$4.4k
Gross profitUS$94121% margin
EBITDA-US$59.1M-1338320% margin
Net income-US$57.4M0.0% margin
Valuation
PER (forward)-8.2x
P/Book1.7x
Beta0.51
Balance sheet & cash
Market capUS$358.4M
Free Cash Flow-US$45.8M
Debt / Equity0%
Profitability & ownership
ROE-55.7%
ROA-32.4%
% insiders3.2%
% institutions94.7%
Last declaration on 11 September 2026
Declarations181 total
100,000 shares@ US$4.180.12% mcap15.5% of flowCommon StockSEC:0001213900-26-098969:0
Canonical exit: 8 Dec 2026 (T+90)
100,000 shares@ US$4.100.12% mcap15.2% of flowCommon StockSEC:0001213900-26-098969:1
Canonical exit: 9 Dec 2026 (T+90)
120,200 shares@ US$4.200.14% mcap13.5% of flowCommon StockSEC:0001213900-26-098970:0
Canonical exit: 8 Dec 2026 (T+90)
79,800 shares@ US$4.250.091% mcap9.0% of flowCommon StockSEC:0001213900-26-098970:1
Canonical exit: 9 Dec 2026 (T+90)
27,500 shares@ US$4.124.7% of flowCommon StockSEC:0001213900-25-121974:0
Canonical exit: 15 Mar 2026 (T+90)
11,665 shares@ US$4.122.3% of flowCommon StockSEC:0001213900-25-121973:0
Canonical exit: 15 Mar 2026 (T+90)
136,000 shares@ US$2.2066.9% of flowCommon StockSEC:0001213900-25-106838:0
Canonical exit: 3 Feb 2026 (T+90)
272,500 shares@ US$2.2025.6% of flowCommon StockSEC:0001213900-25-106837:0
Canonical exit: 3 Feb 2026 (T+90)
500,000 shares@ US$2.2053.2% of flowCommon StockSEC:0001213900-25-106836:0
Canonical exit: 3 Feb 2026 (T+90)
90,000 shares@ US$2.2043.7% of flowCommon StockSEC:0001213900-25-106835:0
Canonical exit: 3 Feb 2026 (T+90)
129,455 shares@ US$0.671.4% of flowCommon StockSEC:0001213900-25-081837:1
Canonical exit: 25 Nov 2025 (T+90)
55,976 shares@ US$0.740.7% of flowCommon StockSEC:0001213900-25-081837:2
Canonical exit: 26 Nov 2025 (T+90)
80,545 shares@ US$0.622.1% of flowCommon StockSEC:0001213900-25-081837:0
Canonical exit: 24 Nov 2025 (T+90)
90,000 shares@ US$0.48541.2% of flowCommon StockSEC:0001213900-25-046087:1
Canonical exit: 17 Aug 2025 (T+90)
60,000 shares@ US$0.52370.9% of flowCommon StockSEC:0001213900-25-046087:2
Canonical exit: 18 Aug 2025 (T+90)
30,000 shares@ US$0.49980.3% of flowCommon StockSEC:0001213900-25-046085:1
Canonical exit: 17 Aug 2025 (T+90)
147,686 shares@ US$0.55691.4% of flowCommon StockSEC:0001213900-25-046085:2
Canonical exit: 18 Aug 2025 (T+90)
172,314 shares@ US$0.44963.4% of flowCommon StockSEC:0001213900-25-046085:0
Canonical exit: 14 Aug 2025 (T+90)
50,000 shares@ US$0.4421.1% of flowCommon StockSEC:0001213900-25-046087:0
Canonical exit: 14 Aug 2025 (T+90)
200,000 shares@ US$0.430319.5% of flowCommon StockSEC:0001213900-25-046088:0
Canonical exit: 14 Aug 2025 (T+90)
228,961 shares@ US$0.451323.7% of flowCommon StockSEC:0001213900-25-046086:0
Canonical exit: 14 Aug 2025 (T+90)
13,000 shares0Common StockSEC:0001213900-24-089971:0
21,118 shares@ US$2.731.6% of flowCommon StockSEC:0001213900-24-077792:1
Canonical exit: 9 Dec 2024 (T+90)
24,120 shares@ US$2.952.0% of flowCommon StockSEC:0001213900-24-077792:2
Canonical exit: 10 Dec 2024 (T+90)
33,014 shares@ US$2.751.5% of flowCommon StockSEC:0001213900-24-077795:1
Canonical exit: 9 Dec 2024 (T+90)
25 of 181 declarations
About Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. is a clinical-stage biopharmaceutical company listed on the Nasdaq (United States) under the ticker RLMD. For French-speaking investors, it fits the profile of a classic high-risk, high-upside small-cap healthcare name, where valuation is driven primarily by clinical execution, regulatory progress, and financing capacity rather than current product revenues. The company was founded in 2004 and is headquartered in Coral Gables, Florida, in the United States. Its strategic focus is on developing differentiated therapies in oncology and selected central nervous system indications, supported by a management team with experience in drug development, clinical operations, and regulatory strategy. ([relmada.com](https://www.relmada.com/for-investors?utm_source=openai))
Relmada’s lead program is NDV-01, an intravesical sustained-release formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer (NMIBC). The product is designed to provide prolonged bladder exposure and controlled local drug release while simplifying in-office administration. The company has disclosed FDA alignment on two registrational pathways, and NDV-01 is progressing toward a Phase 3 RESCUE registrational program expected to start in mid-2026. This program is the main value driver in the near to medium term. Relmada is also advancing sepranolone, a candidate that modulates GABA-A receptor activity to target compulsive behaviors, with a Phase 2 trial planned in Prader-Willi syndrome. ([relmada.com](https://www.relmada.com/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Relmada operates in a crowded biotech landscape dominated by large pharmaceutical companies, specialized oncology players, and numerous clinical-stage peers. Its potential edge lies in NDV-01’s formulation-based differentiation, the commercial and medical attractiveness of NMIBC, and a development strategy focused on areas where unmet need remains high and treatment options are limited or suboptimal. At the same time, the company remains exposed to the standard risks of development-stage biotech: clinical failure, safety issues, regulatory setbacks, funding needs, and dilution risk. ([relmada.com](https://www.relmada.com/?utm_source=openai))
Relmada’s geographic footprint is largely U.S.-based, with operations centered in Florida and a Nasdaq listing in the United States. Recent catalysts include an oversubscribed approximately $160 million PIPE financing announced in March 2026, which strengthened the balance sheet and is expected to support NDV-01’s Phase 3 development. The company has also reported Phase 2 data for NDV-01, provided a positive regulatory update confirming FDA alignment on study design for two separate indications, and issued first-quarter 2026 business and financial updates. For investors in Europe, RLMD should be viewed as a speculative biotech story whose medium-term outcome will depend mainly on upcoming clinical milestones and regulatory validation, rather than near-term earnings power. ([relmada.com](https://www.relmada.com/for-investors/news/detail/333/relmada-therapeutics-announces-oversubscribed-160-0?utm_source=openai))
